Real-world Evidence of Trifluridine/tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer Using an Administrative Claims Database in Japan

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2023 Aug 10

PMID 37562196

Authors

Y Kagawa

E Shinozaki

R Okude

T Tone

Y Kunitomi

M Nakashima

Affiliations

Soon will be listed here.

Abstract

Background: Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC). No results of large real-world data directly comparing FTD/TPI + bevacizumab (BEV) with FTD/TPI or REG monotherapy have been reported. We evaluated the efficacy and safety of FTD/TPI + BEV in a real-world setting.

Materials And Methods: This retrospective study used a Japanese claims database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan). Eligible patients were aged 20 years and over with a diagnosis of mCRC, and received their first dose of FTD/TPI or REG from 2014 to 2021. The primary endpoint was overall survival (OS) in a propensity score matching (PSM) population in which PSM was carried out by matching using a 1 : 1 ratio for the FTD/TPI + BEV group and the control group (FTD/TPI or REG) by propensity score. To enhance robustness, sensitivity analyses of OS were carried out using the inverse probability treatment weighted (IPTW) approach and the analysis in the all eligible population. Secondary endpoints included time to treatment discontinuation (TTD), incidence of adverse events, and post-treatment.

Results: Eligible population was 2369 for the FTD/TPI + BEV group and 9318 for the control group. The PSM population was 1787 for each group. Median OS (mOS) was longer in the FTD/TPI + BEV group compared to the control group [17.0 versus 11.6 months, hazard ratio (HR) = 0.70, P < 0.001] in the PSM population. Similarly, mOS was longer for the FTD/TPI + BEV group compared to that for the control group in IPTW analyses and in the all eligible population (both HRs = 0.68). Median TTD was 3.3 months for the FTD/TPI + BEV group and 1.8 months for the control group in the PSM population (P < 0.001).

Conclusions: Real-world data showed that FTD/TPI + BEV was significantly associated with OS and TTD compared to FTD/TPI or REG. In clinical practice, FTD/TPI + BEV can be a favorable regimen for refractory mCRC.

Citing Articles

Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis.

da Silva L, Saldanha E, da Conceicao L, Martins W, Gismondi R, de Souza Filho E Ecancermedicalscience. 2024; 18:1728.

PMID: 39421178 PMC: 11484657. DOI: 10.3332/ecancer.2024.1728.

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.

Andre T, Van Cutsem E, Taieb J, Fakih M, Prager G, Ciardiello F Curr Treat Options Oncol. 2024; 25(10):1312-1322.

PMID: 39325367 PMC: 11485186. DOI: 10.1007/s11864-024-01261-w.

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.

Hu Y, Du Y, Qiu Z, Zhu C, Wang J, Liang T Front Pharmacol. 2024; 15:1399998.

PMID: 39108741 PMC: 11301057. DOI: 10.3389/fphar.2024.1399998.

A descriptive analysis of real-world oncology biosimilar use in Japan.

Roth J, Rahshenas M, Nowacki G, Masurkar N, Shelbaya A, Tajima K Future Oncol. 2024; 20(25):1837-1850.

PMID: 38864611 PMC: 11486085. DOI: 10.1080/14796694.2024.2352405.

References

Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023; 8(3):101558. PMC: 10220270. DOI: 10.1016/j.esmoop.2023.101558. View

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen L . TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(3):412-420. DOI: 10.1016/S1470-2045(19)30827-7. View

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

Prager G, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E . Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023; 388(18):1657-1667. DOI: 10.1056/NEJMoa2214963. View

Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A . Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open. 2021; 6(2):100093. PMC: 7985393. DOI: 10.1016/j.esmoop.2021.100093. View

Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H . Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol. 2020; 26(1):111-117. DOI: 10.1007/s10147-020-01794-8. View

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W . TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017; 18(9):1172-1181. DOI: 10.1016/S1470-2045(17)30425-4. View

Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H . Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist. 2020; 25(12):e1855-e1863. PMC: 8108052. DOI: 10.1634/theoncologist.2020-0643. View

10.

Hernandez-Quiles C, Bernabeu-Wittel M, Perez-Belmonte L, Macias-Mir P, Camacho-Gonzalez D, Massa B . Concordance of Barthel Index, ECOG-PS, and Palliative Performance Scale in the assessment of functional status in patients with advanced medical diseases. BMJ Support Palliat Care. 2017; 7(3):300-307. DOI: 10.1136/bmjspcare-2015-001073. View

11.

Matsuoka H, Yamada T, Ohta R, Yoshida Y, Watanabe T, Takahashi M . Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). Int J Clin Oncol. 2022; 27(12):1859-1866. DOI: 10.1007/s10147-022-02243-4. View

12.

Mayer R, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N . Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20):1909-19. DOI: 10.1056/NEJMoa1414325. View

13.

Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E . Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2012; 14(1):29-37. DOI: 10.1016/S1470-2045(12)70477-1. View

14.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View